Imunon Inc
IMNN3.750USD
-0.040-1.06%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
12.49MMarket Cap
LossP/E TTM
More Details of Imunon Inc Company
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Imunon Inc Info
Ticker SymbolIMNN
Company nameImunon Inc
IPO dateOct 27, 1993
CEOLindborg (Stacy R)
Number of employees25
Security typeOrdinary Share
Fiscal year-endOct 27
Address997 Lenox Dr Ste 100
CityLAWRENCEVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08648
Phone16098969100
Websitehttps://imunon.com/
Ticker SymbolIMNN
IPO dateOct 27, 1993
CEOLindborg (Stacy R)
Company Executives of Imunon Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
5.65K
+6.60%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
4.54K
+402.99%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
4.31K
+119.57%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.82K
+77.50%
Mr. James E. Dentzer
Mr. James E. Dentzer
Independent Director
Independent Director
3.82K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
3.42K
+246.55%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
2.58K
--
Ms. Kimberly Graper
Ms. Kimberly Graper
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Douglas Vincent Faller, M.D., Ph.D.
Dr. Douglas Vincent Faller, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
5.65K
+6.60%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
4.54K
+402.99%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
4.31K
+119.57%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.82K
+77.50%
Mr. James E. Dentzer
Mr. James E. Dentzer
Independent Director
Independent Director
3.82K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
3.42K
+246.55%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
DRW Securities, LLC
1.79%
Riverview Capital Advisers, LLC
1.12%
The Vanguard Group, Inc.
0.76%
Geode Capital Management, L.L.C.
0.65%
UBS Financial Services, Inc.
0.21%
Other
95.47%
Shareholders
Shareholders
Proportion
DRW Securities, LLC
1.79%
Riverview Capital Advisers, LLC
1.12%
The Vanguard Group, Inc.
0.76%
Geode Capital Management, L.L.C.
0.65%
UBS Financial Services, Inc.
0.21%
Other
95.47%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.17%
Individual Investor
1.06%
Investment Advisor/Hedge Fund
0.65%
Research Firm
0.16%
Bank and Trust
0.14%
Hedge Fund
0.01%
Other
93.81%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
44
176.66K
8.06%
+31.51K
2025Q2
52
152.78K
6.20%
-44.01K
2025Q1
50
565.85K
3.09%
-1.96M
2024Q4
52
608.75K
4.16%
-1.78M
2024Q3
50
1.20M
8.34%
-536.74K
2024Q2
48
484.50K
4.81%
-359.07K
2024Q1
49
447.12K
4.68%
-585.60K
2023Q4
59
755.78K
7.96%
-79.04K
2023Q3
65
452.55K
4.85%
-471.22K
2023Q2
68
440.18K
4.85%
-489.81K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
14.60K
0.67%
+10.86K
+290.27%
Jun 30, 2025
Geode Capital Management, L.L.C.
11.09K
0.51%
+94.00
+0.85%
Jun 30, 2025
Tardugno (Michael H)
5.65K
0.26%
+350.00
+6.60%
May 13, 2025
Fritz (Frederick J)
4.54K
0.21%
+3.63K
+402.99%
Aug 04, 2025
BlackRock Institutional Trust Company, N.A.
4.46K
0.2%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 23, 2025
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Date
Type
Ratio
Jul 23, 2025
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
FAQs
Who are the top five shareholders of Imunon Inc?
The top five shareholders of Imunon Inc are:
The Vanguard Group, Inc. holds 14.60K shares, accounting for 0.67% of the total shares.
Geode Capital Management, L.L.C. holds 11.09K shares, accounting for 0.51% of the total shares.
Tardugno (Michael H) holds 5.65K shares, accounting for 0.26% of the total shares.
Fritz (Frederick J) holds 4.54K shares, accounting for 0.21% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.46K shares, accounting for 0.20% of the total shares.
The Vanguard Group, Inc. holds 14.60K shares, accounting for 0.67% of the total shares.
Geode Capital Management, L.L.C. holds 11.09K shares, accounting for 0.51% of the total shares.
Tardugno (Michael H) holds 5.65K shares, accounting for 0.26% of the total shares.
Fritz (Frederick J) holds 4.54K shares, accounting for 0.21% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.46K shares, accounting for 0.20% of the total shares.
What are the top three shareholder types of Imunon Inc?
The top three shareholder types of Imunon Inc are:
DRW Securities, LLC
Riverview Capital Advisers, LLC
The Vanguard Group, Inc.
DRW Securities, LLC
Riverview Capital Advisers, LLC
The Vanguard Group, Inc.
How many institutions hold shares of Imunon Inc (IMNN)?
As of 2025Q3, 44 institutions hold shares of Imunon Inc, with a combined market value of approximately 176.66K, accounting for 8.06% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 1.85%.
What is the biggest source of revenue for Imunon Inc?
In --, the -- business generated the highest revenue for Imunon Inc, amounting to -- and accounting for --% of total revenue.
